Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
CODICE STUDIO
NCT05317416
TIPOLOGIA
Prima linea giovani, Prima linea anziani
NOME SPONSOR
Pfizer
DESCRIZIONE
Trattamento
Experimental: Arm A – Part 1
Elranatamab:
Drug: Elranatamab
BCMA-CD3 bispecific antibody
Drug: Elranatamab
BCMA-CD3 bispecific antibody
Active Comparator: Arm B – Part 1
Lenalidomide:
Drug: Lenalidomide
Immunomodulatory drug
Drug: Lenalidomide
Immunomodulatory drug
Active Comparator: Arm B – Part 2
Lenalidomide:
Drug: Lenalidomide
Immunomodulatory drug
Drug: Lenalidomide
Immunomodulatory drug
Experimental: Arm C – Part 2
Elranatamab:
Drug: Elranatamab
BCMA-CD3 bispecific antibody
Drug: Elranatamab
BCMA-CD3 bispecific antibody
FARMACI UTILIZZATI